Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Official Title

A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Summary:

Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durability of responses which is essential to improving outcomes following second ASCT.

Trial Description

Primary Outcome:

• Event-free survival (EFS) rate

• Overall response rate (ORR)
• Complete response rate (CRR)
• Minimal residual disease negative (MRD-negative) rate
• Event-free survival (EFS)
• Progression-free survival (PFS)
• Overall survival (OS)
• Toxicity of regimen as measured by frequency of adverse events per the number of participants treated

View this trial on ClinicalTrials.gov